Restructuring playbooks that once sat inside private equity funds are now turning up in listed MedTech groups, with job cuts, asset sales and portfolio reviews all hitting the headlines at the same time as regulatory setbacks and fresh takeover interest. That mix can create sharp winners and quiet laggards. This article walks through three MedTech stocks exposed to these catalysts and explains how investors might think about the risks and potential rewards.

The stocks covered in this article are only a starting sample, and the full screen surfaced 12 more listed MedTech companies with similar restructuring themes and potential catalysts that are not discussed below. To identify and analyze the highest conviction opportunities in this turnaround niche, go straight to the Medical Technology Turnarounds (MedTech with Operational Restructuring and PE Interest) screener.

Bausch + Lomb (BLCO)

Bausch + Lomb is a global eye health company that sells contact lenses, surgical equipment and prescription eye medicines across Vision Care, Surgical and Pharmaceuticals segments. Most revenue currently comes from Vision Care at about US$3.0b, with Pharmaceuticals at roughly US$1.4b and Surgical at about US$0.9b, giving investors exposure across both consumer and procedure driven demand. The stock has a market value of roughly US$6.1b.

Bausch + Lomb sits at the intersection of steady eye care demand and a clear restructuring story, with management pushing cost efficiencies and premium products while targeting a move from losses to profitability in the next few years. The Q2 2026 update showed firmer revenue and margin trends, and a deleveraging plan gives a clearer path on the balance sheet. However, insider selling and a still leveraged capital structure keep the risk side of the equation very real. For investors willing to accept that trade off, the mix of a lower P/S multiple, a full pipeline across contacts, cataract surgery and dry eye, and an active operational playbook makes this an eye health turnaround worth a closer look.

Cost cuts, premium lenses and a busy product pipeline make Bausch + Lomb look like a cleaner story than its headline leverage suggests. To see how that mix of opportunity and balance sheet risk fits together, review the 3 key rewards and 1 important warning sign

Build your own MedTech turnaround shortlist

Bausch + Lomb and the two other MedTech stocks in this article all came from a single screener, but your best ideas will often come from filters tuned to your own process. Use our flexible Screener to mix metrics like valuation, growth, balance sheet strength and risks, or start with one of our curated Investing Ideas.

Haemonetics (HAE)

Haemonetics is a Boston based medical technology company that sells plasma collection systems, hospital blood management tools and vascular closure devices used in procedures such as TAVR and electrophysiology. Most revenue comes from MedSurg at about US$597 million, supported by a segment adjustment line of roughly US$755 million that reflects the way it reports across businesses. The stock has a market value of around US$4.1b.

Haemonetics sits squarely in the MedTech turnaround camp, with management focused on operational excellence, higher margin hospital products and disciplined capital allocation. The company is leaning into platforms like NexSys in plasma, TEG hemostasis systems and VASCADE closure devices. Recent quarters showed stronger profitability and cash generation alongside debt reduction and buybacks. The flip side is a rich P/E, heavy reliance on a few U.S. centric products and a past hit from one off losses. The appeal here is largely a self help margin story that depends on ongoing execution and product adoption.

Haemonetics combines higher margin hospital platforms with buybacks and debt reduction that many investors may be underestimating. Before this self help story develops further, walk through the full analysis report for Haemonetics

Baxter International (BAX)

Baxter International is a large US based MedTech company that supplies IV solutions, infusion systems, injectable drugs and advanced surgical equipment to hospitals and care settings worldwide. It reports around US$3.1b of revenue from Healthcare Systems & Technologies and about US$379 million in Other, with a sizeable segment adjustment line that reflects how management allocates revenue across its portfolio. The stock has a market value of roughly US$13.8b.

Investors looking at Baxter International today are getting a restructuring story tied to hospital demand, new product launches and active balance sheet work rather than a simple steady compounder. Management is pushing cost savings and portfolio clean up while tackling issues like Novum IQ pump corrective actions and a Volara system recall, and at the same time running tender offers to simplify more than US$500 million of debt. The stock trades on a relatively low sales multiple, is described by some analysts as moving from losses toward profitability over the next few years and sits firmly in the camp of companies that private equity might study closely, but execution risk around debt, cash flow and quality controls means the outcome is not preordained.

Baxter International’s restructuring, along with its hospital exposure, may be masking a sharper reset in its core economics. Before the next balance sheet move lands, walk through the Baxter International financial health report

Seeking Alternatives Before The Crowd Moves?

Fresh stock ideas can start breaking out while screens sit unopened. Momentum shifts, under the radar for now, then gets caught once everyone piles in. Consider acting early instead of waiting.

• Track income streams that might hold up when markets wobble by running the 10 dividend fortresses. See which yields still look supported while it matters.
• Spot fast growing tech leaders before headlines catch up by scanning the 56 AI infrastructure stocks. It is built around companies positioned on the rails of AI demand.
• Build your next high conviction watchlist with the 19 high quality undiscovered gems. Stay on top of quality businesses that others could miss if they delay.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.